Stockreport

UroGen Pharma Unveils New Phase 3 Development Plan for UGN-102 at Spotlight Event

UroGen Pharma Ltd. - Ordinary Shares  (URGN) 
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com
PDF New, Single-arm Phase 3 Study Expected to Initiate in Early 2022 PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedi [Read more]